Brian Murphy - NanoVibronix CEO, Director
| NAOV Stock | USD 0.72 0.01 1.37% |
CEO
Mr. Brian M. Murphy is a Chief Executive Officer, Director of the Company. Mr. Murphy has over 25 years of sales, operations and general management experience in medical devices and medical technology fields. From 2012 to 2016, Mr. Murphy served asnational director ofcommercial sales and national director of national accountsat MiMedx Group, Inc., a biotechnology company developing and marketing regenerative biomaterial products, and launched commercial sales and oversaw growth of the business. From 2010 to 2012, Mr. Murphy was the chief executive officer of O2 Insights, Inc., a startup wound care diagnostics company, and led the sale of the company to a strategic buyer, Systagenix in June 2012. From 2008 to 2010, Mr. Murphy served as vice president of sales for ConvaTec, a global medical products and technologies company, and led the negative pressure wound therapy business. From 1992 to 2008, Mr. Murphy served a total of 17 years at Kinetic Concepts, Inc. in various positions overseeing sales, operations and general management. During his employment at KCI, Mr. Murphy led growth of the wound care divisions business from generating 11 million to 550 million in annual revenues, as well as significant growth in the medical services and therapeutic surfaces businesses. Prior to working at KCI, Mr. Murphy served in sales and general manager positions at various companies in the medical device industry, including ATI Medical Equipment Corporationrationration, Mountain Medical Equipment Inc. and Healthdyne Technologies Inc since 2016.
| Age | 67 |
| Tenure | 8 years |
| Address | 969 Pruitt Avenue, Tyler, TX, United States, 77569 |
| Phone | (914) 233-3004 |
| Web | https://www.nanovibronix.com |
Brian Murphy Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brian Murphy against NanoVibronix stock is an integral part of due diligence when investing in NanoVibronix. Brian Murphy insider activity provides valuable insight into whether NanoVibronix is net buyers or sellers over its current business cycle. Note, NanoVibronix insiders must abide by specific rules, including filing SEC forms every time they buy or sell NanoVibronix'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brian Murphy over six months ago Purchase by Brian Murphy of 3378 shares of American Outdoor |
NanoVibronix Management Efficiency
The company has return on total asset (ROA) of (0.2957) % which means that it has lost $0.2957 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4059) %, meaning that it created substantial loss on money invested by shareholders. NanoVibronix's management efficiency ratios could be used to measure how well NanoVibronix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.58 in 2024. Return On Capital Employed is likely to climb to -0.77 in 2024. At this time, NanoVibronix's Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 205.1 K in 2024, whereas Other Current Assets are likely to drop slightly above 44.6 K in 2024.Similar Executives
| Found 7 records | CEO Age | ||
| Andrew Simpson | Heart Test Laboratories | 55 | |
| Eric Olson | SINTX Technologies | 61 | |
| Nestor Jaramillo | Nuwellis | 67 | |
| Michael Stewart | STRATA Skin Sciences | 67 | |
| Jeffrey Frelick | Bone Biologics Corp | 58 | |
| Dolev Rafaeli | STRATA Skin Sciences | 60 | |
| Robert Spignesi | Rapid Micro Biosystems | 55 | |
Management Performance
| Return On Equity | -1.41 | ||||
| Return On Asset | -0.3 |
NanoVibronix Leadership Team
Elected by the shareholders, the NanoVibronix's board of directors comprises two types of representatives: NanoVibronix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NanoVibronix. The board's role is to monitor NanoVibronix's management team and ensure that shareholders' interests are well served. NanoVibronix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NanoVibronix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO Officer | ||
| M Harrison, VP Sales | ||
| Brian Murphy, CEO, Director | ||
| Amir Rippel, Vice Marketing | ||
| Stephen CPA, Chief Officer | ||
| Harold MD, Chief Director | ||
| Lindsey Harrison, Vice Sales |
NanoVibronix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NanoVibronix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.41 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | (0.83) % | ||||
| Operating Margin | (0.82) % | ||||
| Current Valuation | 1.52 M | ||||
| Shares Outstanding | 3.75 M | ||||
| Shares Owned By Insiders | 0.69 % | ||||
| Shares Owned By Institutions | 13.49 % | ||||
| Number Of Shares Shorted | 86.16 K | ||||
| Price To Earning | (5.34) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NanoVibronix Stock Analysis
When running NanoVibronix's price analysis, check to measure NanoVibronix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NanoVibronix is operating at the current time. Most of NanoVibronix's value examination focuses on studying past and present price action to predict the probability of NanoVibronix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NanoVibronix's price. Additionally, you may evaluate how the addition of NanoVibronix to your portfolios can decrease your overall portfolio volatility.